Literature DB >> 33381057

Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown.

Roberta Baschi1, Antonina Luca2, Alessandra Nicoletti2, Maria Caccamo1, Calogero Edoardo Cicero2, Concetta D'Agate2, Lucia Di Giorgi1, Giuseppe La Bianca1, Tiziana Lo Castro2, Mario Zappia2, Roberto Monastero1.   

Abstract

Objective: The effects of the COVID-19 lockdown on subjects with prodromal phases of dementia are unknown. The aim of this study was to evaluate the motor, cognitive, and behavioral changes during the COVID-19 lockdown in Italy in patients with Parkinson's disease (PD) with and without mild cognitive impairment (PD-MCI and PD-NC) and in patients with MCI not associated with PD (MCInoPD).
Methods: A total of 34 patients with PD-NC, 31 PD-MCI, and 31 MCInoPD and their caregivers were interviewed 10 weeks after the COVID-19 lockdown in Italy, and changes in cognitive, behavioral, and motor symptoms were examined. Modified standardized scales, including the Neuropsychiatric Inventory (NPI) and the Movement Disorder Society, Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II, were administered. Multivariate logistic regression was used to evaluate associated covariates by comparing PD-NC vs. PD-MCI and MCInoPD vs. PD-MCI.
Results: All groups showed a worsening of cognitive (39.6%), pre-existing (37.5%), and new (26%) behavioral symptoms, and motor symptoms (35.4%) during the COVID-19 lockdown, resulting in an increased caregiver burden in 26% of cases. After multivariate analysis, PD-MCI was significantly and positively associated with the IADL lost during quarantine (OR 3.9, CI 1.61-9.58), when compared to PD-NC. In the analysis of MCInoPD vs. PD-MCI, the latter showed a statistically significant worsening of motor symptoms than MCInoPD (OR 7.4, CI 1.09-45.44). Regarding NPI items, nighttime behaviors statistically differed in MCInoPD vs. PD-MCI (16.1% vs. 48.4%, p = 0.007). MDS-UPDRS parts I and II revealed that PD-MCI showed a significantly higher frequency of cognitive impairment (p = 0.034), fatigue (p = 0.036), and speech (p = 0.013) than PD-NC. On the contrary, PD-MCI showed significantly higher frequencies in several MDS-UPDRS items compared to MCInoPD, particularly regarding pain (p = 0.001), turning in bed (p = 0.006), getting out of bed (p = 0.001), and walking and balance (p = 0.003).
Conclusion: The COVID-19 quarantine is associated with the worsening of cognitive, behavioral, and motor symptoms in subjects with PD and MCI, particularly in PD-MCI. There is a need to implement specific strategies to contain the effects of quarantine in patients with PD and cognitive impairment and their caregivers.
Copyright © 2020 Baschi, Luca, Nicoletti, Caccamo, Cicero, D'Agate, Di Giorgi, La Bianca, Lo Castro, Zappia and Monastero.

Entities:  

Keywords:  COVID-19; Parkinson's disease; behavioral symptoms; caregiver burden; cognitive impairment; motor impairment; quarantine

Year:  2020        PMID: 33381057      PMCID: PMC7768013          DOI: 10.3389/fpsyt.2020.590134

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


  20 in total

Review 1.  Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review.

Authors:  Fardin Nabizadeh; Zahrasadat Seyedalhosseini; Mohammad Balabandian; Mohammad Reza Rostami
Journal:  J Clin Neurosci       Date:  2022-06-28       Impact factor: 2.116

2.  Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.

Authors:  Katarina Rukavina; Victor McConvey; Kallol Ray Chaudhuri; Janis Miyasaki
Journal:  Int Rev Neurobiol       Date:  2022-04-27       Impact factor: 4.280

3.  The effect of COVID-19 isolation measures on the cognition and mental health of people living with dementia: A rapid systematic review of one year of quantitative evidence.

Authors:  Aida Suárez-González; Jayeeta Rajagopalan; Gill Livingston; Suvarna Alladi
Journal:  EClinicalMedicine       Date:  2021-07-31

4.  The Effective Cognitive Assessment and Training Methods for COVID-19 Patients With Cognitive Impairment.

Authors:  Dong Wen; Jian Xu; Zhonglin Wu; Yijun Liu; Yanhong Zhou; Jingjing Li; Shaochang Wang; Xianlin Dong; M Iqbal Saripan; Haiqing Song
Journal:  Front Aging Neurosci       Date:  2022-01-11       Impact factor: 5.750

5.  COVID-19-Related Lifestyle Changes among Community-Dwelling Older Adult Day-Care Users: A Qualitative Study.

Authors:  Akira Teramura; Yumi Kimura; Kosuke Hamada; Yasuko Ishimoto; Masato Kawamori
Journal:  Int J Environ Res Public Health       Date:  2021-12-27       Impact factor: 3.390

6.  Examination of the cognitive function of Japanese community-dwelling older adults in a class for preventing cognitive decline during the COVID-19 pandemic.

Authors:  Minoru Kouzuki; Shota Furukawa; Keisuke Mitani; Katsuya Urakami
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

Review 7.  Social and psychological impact of the COVID-19 pandemic on people with Parkinson's disease: a scoping review.

Authors:  S K Brooks; D Weston; N Greenberg
Journal:  Public Health       Date:  2021-09-01       Impact factor: 4.984

8.  Impact of COVID-19 Pandemic on Parkinson's Disease: A Tale of Fears and Sorrows!

Authors:  Niraj Kumar; Ravi Gupta
Journal:  Ann Indian Acad Neurol       Date:  2021-04-06       Impact factor: 1.383

Review 9.  Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps.

Authors:  Kathy Y Liu; Robert Howard; Sube Banerjee; Adelina Comas-Herrera; Joanne Goddard; Martin Knapp; Gill Livingston; Jill Manthorpe; John T O'Brien; Ross W Paterson; Louise Robinson; Martin Rossor; James B Rowe; David J Sharp; Andrew Sommerlad; Aida Suárez-González; Alistair Burns
Journal:  Int J Geriatr Psychiatry       Date:  2021-05-27       Impact factor: 3.850

10.  Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson's Disease in Germany (Care4PD).

Authors:  Odette Fründt; Anne-Marie Hanff; Tobias Mai; Christiane Kirchner; Emma Bouzanne des Mazery; Ali Amouzandeh; Carsten Buhmann; Rejko Krüger; Martin Südmeyer
Journal:  Brain Sci       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.